Acromegaly — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Cost-effectiveness of pasireotide long-acting release in acromegaly: a systematic literature review and methodology assessment.
Gilis-Januszewska Aleksandra et al. — Journal of medical economics (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41518621/
- 2.
A QbD-informed study of permeation enhancer-octreotide nanoscale interactions influencing performance in pullulan buccal films.
Malhotra Sahil et al. — International journal of pharmaceutics (10 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41771310/
- 3.
The silent surden: Alexithymia and quality of life in acromegaly patients.
Soltanova Lala et al. — Endocrine (2 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41925751/
- 4.
Ageing and pituitary neuroendocrine tumours (PitNETs): from bench to bedside.
De Alcubierre Dario et al. — Endocrine-related cancer (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41849686/
- 5.
Cost-effectiveness of personalized medical treatment in acromegaly: a post hoc analysis of the ACROFAST study.
Marques-Pamies Montserrat et al. — Journal of the Endocrine Society (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41798894/
Clinical Trials — Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
Completed — Phase 4 — Pfizer
https://clinicaltrials.gov/study/NCT00068042
- 2.
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
Completed — Phase 4 — Ipsen
https://clinicaltrials.gov/study/NCT00216398
- 3.
A Phase 1 Study of TE-8214 Solution in Healthy Volunteers
Completed — Phase 1 — Immunwork, Inc.
https://clinicaltrials.gov/study/NCT06372652
- 4.
Pegvisomant And Sandostatin LAR Combination Study
Completed — Phase 4 — Pfizer
https://clinicaltrials.gov/study/NCT00068029
- 5.
An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
Completed — Phase 2 — Novartis Pharmaceuticals
https://clinicaltrials.gov/study/NCT00171730
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Acromegaly
Acromegaly is a rare hormonal disorder caused by excess growth hormone production, usually from a benign pituitary tumour. It leads to abnormal growth of hands, feet, and facial features, along with numerous systemic complications. An estimated 1,500 Australians live with acromegaly, and diagnosis is often delayed by a decade due to its gradual onset.
Most Recent Research
BACKGROUND: Acromegaly is a rare and progressive condition caused by excessive secretion of growth hormone and insulin-like growth factor type 1. Pasireotide long-acting release (LAR) is indicated as a second-line therapy for adults with acromegaly who are unsuitable for or unresponsive to surgery and inadequately controlled with first-generation somatostatin receptor ligands (FGSRLs). Although its efficacy and safety have already been established, its cost-effectiveness remains unclear. The primary objective of this study was to systematically assess the cost-effectiveness of pasireotide LAR compared to other second-line medical options, particularly pegvisomant. METHODS: A systematic literature review was conducted in May 2024 in Medline, Medline In Process, Web of Science, and the Centre for Reviews and Dissemination (CRD), York. Studies were eligible if they were full or partial economic analyses of pasireotide LAR as a second-line pharmacological treatment for adult patients with acromegaly. Studies not available in English and publications prior to 2009 were excluded. Included articles were assessed for transparency using the appropriate checklists. Data extraction focused on costs, incremental cost-effectiveness ratios and quality-adjusted life years. Formal data synthesis of outcomes was not undertaken due to the small number of studies and notable heterogeneity between them. Methodological assessment involving the evaluation of model inputs, data sources, and their alignment with the evidence on the course of disease and clinical practice was performed to examine the main factors contributing to discrepancies in cost-effectiveness outcomes and assess the credibility of the results. RESULTS: Of 160 records identified, six publications met the inclusion criteria. Their findings demonstrated variability. The critical assessment highlighted considerable variability in methodological rigor among the included studies. CONCLUSIONS: Evidence on pasireotide LAR's cost-effectiveness versus pegvisomant regimens remains inconclusive. Although two studies indicated that pegvisomant is more cost-effective, the study with the highest methodological credibility found that pasireotide LAR is a cost-effective alternative.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.